Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Rasgon, Natalie L ^a   Geist, Cheri L ^b   Kenna, Heather A ^a   Wroolie, Tonita E ^a   Williams, Katherine E ^a   Silverman, Daniel H S ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; FLUORODEOXYGLUCOSE F 18; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; GESTAGEN;

ADULT; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DEMENTIA; DRUG EFFECT; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; FEMALE; FRONTAL CORTEX; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; LONGITUDINAL STUDY; MEDICATION COMPLIANCE; MIDDLE FRONTAL GYRUS; MOOD; OUTCOME ASSESSMENT; PARIETAL CORTEX; PATIENT COMPLIANCE; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; POSTMENOPAUSE; PRECUNEUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; AGED; BRAIN; DIAGNOSTIC USE; DRUG EFFECTS; ESTROGEN THERAPY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK; SCINTISCANNING; TIME;

AGED; BRAIN; DEMENTIA; ESTROGEN REPLACEMENT THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; POSTMENOPAUSE; PROGESTINS; PROSPECTIVE STUDIES; RISK; TIME FACTORS;

EID: 84897976813     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089095     Document Type: Article

References (69)

1. Brann D, Dhandapani K, Wakade C, Mahesh V, Khan M (2007) Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 72: 381-405. (Pubitemid 46602478)
2. Suzuki S, Brown C, Wise P (2006) Mechanisms of neuroprotection by estrogen. Endocrine 29: 209-215. (Pubitemid 44097364)
3. Frick KM (2012) Building a better hormone therapy? How understanding the rapid effects of sex steroid hormones could lead to new therapeutics for agerelated memory decline. Behav Neurosci 126: 29-53.
4. Henderson VW (2011) Gonadal hormones and cognitive aging: a midlife perspective. Womens Health (Lond Engl) 7: 81-93.
5. Gleason CE, Carlsson CM, Johnson S, Atwood C, Asthana S (2005) Clinical pharmacology and differential cognitive efficacy of estrogen preparations. Ann N Y Acad Sci 1052: 93-115. (Pubitemid 41338961)
6. Hu L, Yue Y, Zuo P, Jin Z, Feng F, et al. (2006) Evaluation of neuroprotective effects of long-term low dose hormone replacement therapy on postmenopausal women brain hippocampus using magnetic resonance scanner. Chin Med Sci J 21: 214-218. (Pubitemid 46133451)
7. Boccardi M, Ghidoni R, Govoni S, Testa C, Benussi L, et al. (2006) Effects of hormone therapy on brain morphology of healthy postmenopausal women: a Voxel-based morphometry study. Menopause 13: 584-591. (Pubitemid 44088351)
8. Lord C, Buss C, Lupien S, Pruessner J (2008) Hippocampal volumes are larger in postmenopausal women using estrogen therapy compared to past users, never users and men: A possible window of opportunity effect. Neurobiol Aging 29: 95-101. (Pubitemid 350102707)
9. Raz N, Rodrigue KM, Kennedy KM, Acker JD (2004) Hormone replacement therapy and age-related brain shrinkage: regional effects. Neuroreport 15: 2531-2534. (Pubitemid 39579347)
10. Robertson D, Craig M, van Amelsvoort T, Daly E, Moore C, et al. (2009) Effects of estrogen therapy on age-related differences in gray matter concentration. Climacteric 12: 301-309.
11. Shumaker S, Legault C, Kuller L, Rapp S, Thal L, et al. (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291: 2947-2958. (Pubitemid 38802684)
12. Shumaker S, Legault C, Rapp S, Thal L, Wallace R, et al. (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289: 2651-2662. (Pubitemid 37430136)
13. Harman S, Naftolin F, Brinton E, Judelson D (2005) Is the estrogen controversy over? Deconstructing the Women's Health Initiative Study: a critical evaluation of the evidence. Annals of the New York Academy of Science 1052: 43-56. (Pubitemid 41338957)
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34: 939-944. (Pubitemid 14076461)
15. Small G, Mazziotta J, Collins M, Baxter L, Phelps M, et al. (1995) Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273: 942-947.
16. Small G, La Rue A, Komo S, Kaplan A, Mandelkern M (1995) Predictors of cognitive change in middle-aged and older adults with memory loss. Am J Psychiatry 152: 1757-1764.
17. Silverman D, Small G, Phelps M (1999) Clinical Value of Neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and Other Parameters for Early Identification of Alzheimer's Disease. Clin Positron Imaging 2: 119-130.
18. Wolf H, Jelic V, Gertz H, Nordberg A, Julin P, et al. (2003) A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurology Scandinavica 179: 52-76.
19. Bassett S, Yousem D, Cristinzio C, Kusevic I, Yassa M, et al. (2006) Familial risk for Alzheimer's disease alters fMRI activation patterns. Brain 129: 1229-1239.
20. Houston W, Delis D, Lansing A, Jacobson M, Cobell K, et al. (2005) Executive function asymmetry in older adults genetically at-risk for Alzheimer's disease: verbal versus design fluency. Journal of the International Neuropsychological Society 11: 863-870. (Pubitemid 43379937)
21. Jacobson M, Delis D, Bondi M, Salmon D (2005) Asymmetry in auditory and spatial attention span in normal elderly genetically at risk for Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology 27: 240-253. (Pubitemid 40389051)
22. Jacobson M, Delis D, Lansing A, Houston W, Olsen R, et al. (2005) Asymmetries in global-local processing ability in elderly people with the apolipoprotein e-episilon4 allele. Neuropsychology 19: 822-829. (Pubitemid 41803529)
23. Johnson SC, Schmitz TW, Trivedi MA, Ries ML, Torgerson BM, et al. (2006) The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J Neurosci 26: 6069-6076. (Pubitemid 44334754)
24. Wishart H, Saykin A, Rabin L, Santulli R, Flashman L, et al. (2006) Increased brain activiation during working memory in cognitively intact adults with the APOE epsilon4 allele. American Journal of Psychiatry: 1603-1610. (Pubitemid 44465762)
25. Smith C, Andersen A, Kryscio R, Schmitt F, Kindy M, et al. (1999) Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology 53: 1391-1396. (Pubitemid 29491926)
26. Bookheimer S, Strojwas M, Cohen M, Saunders A, Pericak-Vance M, et al. (2000) Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 343: 450-456. (Pubitemid 30646483)
27. Bondi M, Houston W, Eyler L, Brown G (2005) fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology 64: 501-508. (Pubitemid 40189870)
28. Han S, Houston W, Jak A, Eyler L, Nagel B, et al. (2007) Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response. Neurobiology of Aging 28: 238-247. (Pubitemid 44894633)
29. Smith C, Andersen A, Kryscio R, Schmitt F, Kindy M, et al. (2002) Women at risk for AD show increased parietal activation during a fluency task. Neurology 58: 1197-1202. (Pubitemid 34411863)
30. Hom J, Turner M, Risser R, Bonte F, Tintner R (1994) Cognitive deficits in asymptomatic first-degree relatives of Alzheimer's disease patients. Journal of Clinical and Experimental Neuropsychology 16: 568-576. (Pubitemid 24228969)
31. LaRue A, Matsuyama S, McPherson S, Sherman J, Jarvik L (1992) Cognitive performance in relatives of patients with probably Alzheimer's disease: an age at onset effect? Journal of Clinical and Experimental Neuropsychology 14: 533-538.
32. LaRue A, O'Hara R, Matsuyama S, Jarvik L (1995) Cognitive changes in young-old adults: effect of family history of dementia. Journal of Clinical and Experimental Neuropsychology 17: 65-70.
33. Jarvik L, Harrison T, Holt L, Jimenez E, Larson S, et al. (2005) Middle-aged children of Alzheimer parents, a pilot study: stable neurocognitive performance at 20-year follow-up. JGPN 18: 187-191. (Pubitemid 41736381)
34. Small G, Leuchter A, Mandelkern M, LaRue A, Okonek A, et al. (1993) Clinical, neuroimaging, and environmental risk differences in monozygotic females twins appearing discordant for dementia of the Alzheimer type. Archives of Neurology 50: 209-219. (Pubitemid 23054806)
35. Newman S, Warrington E, Kennedy A, Rossor M (1994) The earliest cognitive change in a person with familial Alzheimer's disease: presymptomatic neuropsychological features in a pedigree with familial Alzheimer's disease confirmed at necropsy. Journal of Neurology, Neurosurgery, & Psychiatry 57: 967-972. (Pubitemid 24251063)
36. Lehtovirta M, Soininen H, Helisalmi S, Mannermaa A, Helkala E, et al. (1996) Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Neurology 46: 413-419. (Pubitemid 26081323)
37. Lehtovirta M, Soininen H, Laakso M, Partanen K, Helisalmi S, et al. (1996) SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E episilon 4 allele. Journal of Neurology, Neurosurgery, & Psychiatry 60: 644-649.
38. Silverman DH, Geist CL, Kenna HA, Williams K, Wroolie T, et al. (2011) Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. Psychoneuroendocrinology 36: 502-513.
39. Rasgon NL, Silverman D, Siddarth P, Miller K, Ercoli LM, et al. (2005) Estrogen use and brain metabolic change in postmenopausal women. Neurobiol Aging 26: 229-235. (Pubitemid 39600579)
40. Hamilton M (1960) A rating scale for depression. Journal of neurology, neurosurgery, and psychiatry 23: 56-62.
41. Folstein M, Folstein S, McHugh P (1975) "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
42. Polkowski K, Mazurek A (2000) Biological properties of genistein. A review of in vitro and vivo data. Acta Pol Pharm 57: 135-155. (Pubitemid 30326231)
43. Vincent A, Fitzpatrick L (2000) Soy isoflavones: are they useful in menopause? Mayo Clin Proceed 75: 1174-1184.
44. Friston KJ, Stephan KE, Lund TE, Morcom A, Kiebel S (2005) Mixed-effects and fMRI studies. Neuroimage 24: 244-252. (Pubitemid 39611045)
45. Silverman D, Dy C, Castellon S, Lai J, Pio B, et al. (2007) Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 103: 303-311. (Pubitemid 46944511)
46. Silverman D (2009) PET in the Evaluation of Alzheimer's Disease and Related Disorders. New York: Springer.
47. Mielke R, Schroder R, Fink GR, Kessler J, Herholz K, et al. (1996) Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol 91: 174-179. (Pubitemid 26021405)
48. Silverman D, Mosconi L, Ercoli L, Chen W, Small G (2008) Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Semin Nucl Med 38: 251-261. (Pubitemid 351726326)
49. Phelps M, Shelbert H (1986) Positron emission tomography and autoradiography: Principles and applications for the brain and heart. New York: Raven.
50. Mazziotta J, Frackowiak R, Phelps M (1992) The use of positron emission tomoraphy in the clinical assessment of dementia. Semin Nucl Med 22: 233-246.
51. Duara R, Grady C, Haxby J, Sundaram M, Cutler N, et al. (1986) Positron emission tomography in Alzheimer's disease. Neurology 36: 879-887. (Pubitemid 16098229)
52. Meguro K, Blaizot X, Kondoh Y, Le Mestric C, Baron J, et al. (1999) Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. Brain 122: 1519-1531. (Pubitemid 29374127)
53. Minoshima S, Giordani B, Berent S, Frey K, Foster N, et al. (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Annals of Neurology 42: 85-94. (Pubitemid 27304784)
54. Rasgon N, Small G, Giddarth P, Miller K, Ercoli L, et al. (2001) Estrogen use and brain metabolic change in older adults. A preliminary report. Psychiatry Res 107: 11-18. (Pubitemid 32706502)
55. Small G, Ercoli L, Silverman D, Huang S, Komo S, et al. (2000) Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. PNAS 97: 6037-6042. (Pubitemid 30367519)
56. Kantarci K, Jack CR Jr., Xu YC, Campeau NG, O'Brien PC, et al. (2000) Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 55: 210-217. (Pubitemid 30604620)
57. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, et al. (2003) Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 30: 1104-1113. (Pubitemid 36988222)
58. Kordower JH, Chu Y, Stebbins GT, DeKosky ST, Cochran EJ, et al. (2001) Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 49: 202-213. (Pubitemid 32157996)
59. Maki P, Resnick S (2000) Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol Aging 21: 373-383. (Pubitemid 30387097)
60. Smith Y, Love T, Persad C, Tkaczyk A, Nichols T, et al. (2006) Impact of combined estradiol and norethindrone therapy on visuospatial working memory assessed by functional magnetic resonance imaging. J Clin Endocrinol Metab 91: 4476-4481. (Pubitemid 44833426)
61. Wroolie TE, Kenna HA, Williams KE, Powers BN, Holcomb M, et al. (2011) Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17beta-estradiol versus conjugated equine estrogens. Am J Geriatr Psychiatry 19: 792-802.
62. Pardo JV, Lee JT, Sheikh SA, Surerus-Johnson C, Shah H, et al. (2007) Where the brain grows old: decline in anterior cingulate and medial prefrontal function with normal aging. Neuroimage 35: 1231-1237. (Pubitemid 46507815)
63. Rasgon N, Kenna H, Geist C, Powers B, Wroolie T, et al. Regional cerebral metabolism and neuropsychological performance among healthy postmenopausal users of estrogen therapy; 2008; Washington, D.C.
64. Genon S, Collette F, Moulin CJ, Lekeu F, Bahri MA, et al. (2012) Verbal learning in Alzheimer's disease and mild cognitive impairment: fine-grained acquisition and short-delay consolidation performance and neural correlates. Neurobiol Aging.
65. Coker LH, Espeland MA, Rapp SR, Legault C, Resnick SM, et al. (2010) Postmenopausal hormone therapy and cognitive outcomes: the Women's Health Initiative Memory Study (WHIMS). J Steroid Biochem Mol Biol 118: 304-310.
66. Henderson VW (2006) Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience 138: 1031-1039.
67. Barnes DE, Yaffe K, Byers AL, McCormick M, Schaefer C, et al. (2012) Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 69: 493-498.
68. Maeshima H, Baba H, Nakano Y, Satomura E, Namekawa Y, et al. (2012) Residual memory dysfunction in recurrent major depressive disorder-a longitudinal study from Juntendo University Mood Disorder Project. J Affect Disord 143: 84-88.
69. Olazaran J, Trincado R, Bermejo-Pareja F (2013) Cumulative effect of depression on dementia risk. Int J Alzheimers Dis 2013: 457175.